Clinical Trial Update: Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating ibrutinib for prevention of chronic graft-versus-host disease in patients receiving donor stem cell transplants and is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Neoplasms

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Mayo Clinic | Conditions: Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Status: RECRUITING